Clostridium Difficile Diagnostics and Treatment Market - Global Industry Insights, and Forecast, 2022 - 2028

Clostridium Difficile Diagnostics and Treatment Market - Global Industry Insights, and Forecast, 2022 - 2028

Clostridium difficile infection (CDI) is diagnosed with the help of conventional laboratory testing methods, however, rapid point-of-care diagnostic tests are also available, which can save time and costs significantly. Diagnostic assays used for detection of CDI include enzyme immunoassays (EIAs) for toxins A/B. However, these are no longer considered stand-alone primary tests due to poor sensitivity. Other tests include glutamate dehydrogenase enzyme immunoassay and molecular assay based on polymerase chain reaction. Isothermal amplification technology has also been approved by the U.S. Food & Drug Administration for diagnosis of CDI. Manufacturers such as Cepheid, BD Diagnostics, DiaSorin, Inc., Abbott Laboratories, Thermo Fisher Diagnostics, and Luminex Corporation offer advanced diagnostic tests for clostridium difficile infection. For instance, Cepheid GeneXpert test, Nanosphere Verigene SP by Luminex Corporation offer sensitivity and timely results for clostridium difficile infection.
Market Dynamics
Factors such as rising prevalence of clostridium difficile infection, availability of precise and advanced diagnostic techniques such as real time-polymerase chain reaction (RT-PCR), and presence of generic versions of standard antibiotics such as metronidazole is expected to boost growth of the clostridium difficile diagnostics and treatment market over the forecast period. Furthermore, various organizations and manufacturers are working towards increasing awareness about clostridium difficile infection and its severity. For instance, in March 2018, C Diff Foundation awarded its “Making a Difference” award to CutisPharma, Inc.—a pharmaceutical company, for contribution of the company towards increasing awareness and expanding treatment options.
Key features of the study:

This report provides in-depth analysis of clostridium difficile diagnostics and treatment market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global clostridium difficile diagnostics and treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key companies covered as a part of this study include Roche AG, Thermo Fisher Scientific Inc., Merck & Co., Inc., Pfizer, Inc., Actelion Pharmaceuticals, Abbott Laboratories, Trinity Biotech, Summit Therapeutics, Sanofi S.A., Novartis AG, and AstraZeneca Plc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global clostridium difficile diagnostics and treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the clostridium difficile diagnostics and treatment market

Detailed Segmentation:

Global Clostridium Difficile Diagnostics and Treatment Market, By Product Type:

By Drug       

Metronidazole
Vancomycin
Fidaxomicin
Bezlotoxumab

By Diagnostic Test

Enzyme Immunoassays
Real-Time Polymerase Chain Reaction (RT-PCR)
Nucleic Amplification Tests (NAAT)
Others

Global Clostridium Difficile Diagnostics and Treatment Market, By Distribution Channel:

Hospitals & Clinics
Diagnostic Laboratories
Pharmacies  

Global Clostridium Difficile Diagnostics and Treatment Market, By Geography:

North America

By Product Type:

By Drug       

Metronidazole
Vancomycin
Fidaxomicin
Bezlotoxumab

By Diagnostic Test

Enzyme Immunoassays
Real-Time Polymerase Chain Reaction (RT-PCR)
Nucleic Amplification Tests (NAAT)
Others

By Distribution Channel:

Hospitals & Clinics
Diagnostic Laboratories
Pharmacies  

By Country:

U.S.
Canada

Europe

By Product Type:

By Drug       

Metronidazole
Vancomycin
Fidaxomicin
Bezlotoxumab

By Diagnostic Test

Enzyme Immunoassays
Real-Time Polymerase Chain Reaction (RT-PCR)
Nucleic Amplification Tests (NAAT)
Others

By Distribution Channel:

Hospitals & Clinics
Diagnostic Laboratories
Pharmacies  

By Country:

U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe

Asia Pacific

By Product Type:

By Drug       

Metronidazole
Vancomycin
Fidaxomicin
Bezlotoxumab

By Diagnostic Test

Enzyme Immunoassays
Real-Time Polymerase Chain Reaction (RT-PCR)
Nucleic Amplification Tests (NAAT)
Others

By Distribution Channel:

Hospitals & Clinics
Diagnostic Laboratories
Pharmacies  

By Country:

China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific

Latin America

By Product Type:

By Drug       

Metronidazole
Vancomycin
Fidaxomicin
Bezlotoxumab

By Diagnostic Test

Enzyme Immunoassays
Real-Time Polymerase Chain Reaction (RT-PCR)
Nucleic Amplification Tests (NAAT)
Others

By Distribution Channel:

Hospitals & Clinics
Diagnostic Laboratories
Pharmacies  

By Country:

Brazil
Mexico
Rest of Latin America

Middle East

By Product Type:

By Drug       

Metronidazole
Vancomycin
Fidaxomicin
Bezlotoxumab

By Diagnostic Test

Enzyme Immunoassays
Real-Time Polymerase Chain Reaction (RT-PCR)
Nucleic Amplification Tests (NAAT)
Others

By Distribution Channel:

Hospitals & Clinics
Diagnostic Laboratories
Pharmacies  

By Country:

GCC
Israel
Rest of Middle East

Africa

By Product Type:

By Drug       

Metronidazole
Vancomycin
Fidaxomicin
Bezlotoxumab

By Diagnostic Test

Enzyme Immunoassays
Real-Time Polymerase Chain Reaction (RT-PCR)
Nucleic Amplification Tests (NAAT)
Others

By Distribution Channel:

Hospitals & Clinics
Diagnostic Laboratories
Pharmacies  

By Country:

Central Africa
South Africa
North Africa

Company Profiles

Roche AG *

Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments

Thermo Fisher Scientific
Merck & Co., Inc.
Pfizer, Inc.
Actelion Pharmaceuticals, Inc.
Abbott Laboratories
Trinity Biotech
Summit Therapeutics
Sanofi S.A.
Novartis AG
AstraZeneca Plc

 “*” marked represents similar segmentation in other categories in the respective section.